Elevance Health (ELV)
Salud — seguros médicos administrados
One of the largest U.S. health insurers by medical membership, a Blue Cross Blue Shield brand licensee in 14 states, is going through the sharpest margin compression in its recent history (the operating margin fell from 5.3% in 2022 to 2.7% over the trailing twelve months) due to structurally elevated medical cost; the company's own guidance marks 2026 as the floor and promises recovery starting in 2027, but at the market price the base case barely preserves value.
- Price
- $399.64
- Intrinsic value (5y, base)
- $571
- Total annual return (5y)
- 9.2%
- Status (nominal)
- Fairly valued
- Margin of safety
- +19%
The essentials
- Consolidated operating margin fell from 5.29% (FY2022) to 2.71% (trailing twelve months through June 2026), four consecutive years of compression from elevated medical cost.
- July 2026 guidance: diluted earnings per share of at least $20.10 (GAAP) and $27.00 (adjusted), with management itself marking 2026 as the base year for a return to growth of at least 12% in 2027.
- Medicare Advantage membership fell nearly 16% year over year through the second quarter of 2026, reversing FY2025's 7.9% growth — a signal of active exit from unprofitable markets.
Intrinsic value — two valuation methods
Total return at 5 years: 9.2%/year = 7.4% appreciation + 1.8% dividend. The target price ($571) is ex-dividend; the $41 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $577 · Multiples $494) exceeds the market price ($400).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $400 trades ~19.1% below its value discounted to today (~$494); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — En valor: the target price ($571) plus dividends yield between the 4% floor and the 10% average return — a reasonable return, though without the margin of a great investment.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$311.
Thesis
The business
Elevance is a health insurer of meaningful scale with a contractually protected brand (Blue Cross Blue Shield) in 14 states, but it is going through the most severe margin compression of its recent history due to a medical cost that has exceeded premium collections for four consecutive years. Medicare Advantage membership, which had grown strongly in 2025, reversed sharply in 2026.
The valuation
It is valued as a sum of the parts: Health Benefits by EV/EBIT at the floor of the managed health insurance band (medical cost pressure), CarelonRx in the middle tier (dependence on CVS), and Carelon Services near the ceiling (higher growth and margin expansion). The result is Fairly valued, with an estimated total return over 5 years of +9% against the market price.
The margin of safety
It trades close to intrinsic value, far from the required margin of safety. The market price ($394.20) is close to the calculated 5-year value under the base case, leaving little cushion against a scenario where medical cost does not normalize as guided by the company itself.
What to watch
The central disconfirmer is whether the guidance of adjusted earnings per share of at least $27.00 for 2026 and the return to growth of at least 12% in 2027 are met: if medical cost remains elevated beyond what was guided, or if the exit from Medicare Advantage markets keeps eroding membership without price mix compensating for it, the recovery thesis breaks down and the exit multiple should compress toward the floor of the band.
Educational / informational. Does not constitute investment advice.